Nova Mentis Life Science Corp (CSE: NOVA) (FSE: HN3Q) (OTCPK: NMLSF)

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

Nova is the first company to achieve psilocybin orphan drug
designation in both the U.S. and European Union for the treatment of
fragile X syndrome, the leading genetic cause of symptoms
related to autism spectrum disorder.

This provides us with financial benefits, market exclusivity,
research assistance and access to grants.

Autism Spectrum Disorder and Fragile X Syndrome Observational Study

Learn More

Latest News

Dr. Hausman at Fragile-X Conference

18th NFXF International Fragile X Conference

Dr. Marvin S. Hausman, the Chairman of Nova’s Scientific Advisory Board, delivered a presentation titled: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome at the 18th NFXF International Fragile X Conference in July 2022.

Nova’s recent research results showed that a very low microdose formulation of our proprietary psilocybin drug (NM-1001) significantly modulated behavioural and cognitive defects in a genetic model of FXS.

July 11, 2022

Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference

Vancouver, British Columbia – July 11, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it will be discussing the therapeutic potential of oral microdose psilocybin for the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS) during a...

June 22, 2022

Nova Mentis to Present at the H.C. Wainwright Mental Health Conference

Vancouver, British Columbia – June 22, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it will be presenting at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond on June 27, 2022.